Ablation of Src Family Kinases FGR in hosts reduces confers response of high-grade ovarian cancer to immune checkpoint blockade treatment

被引：0
|
作者：
Ernst, M. [1 ]
Poh, A. [2 ]
Christie, E. [3 ]
机构：
[1] Olivia Newton John Canc Res Inst, Canc & Inflammat, Heidelberg, Vic, Australia
[2] Olivia Newton John Canc Res Inst, Canc Inflammat Lab, Heidelberg, Vic, Australia
[3] Peter MacCallum Canc Ctr, Canc Evolut & Metastasis Program, Melbourne, Vic, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB-506
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 43 条
  • [21] Single-cell and spatial transcriptomic characterization of treatment resistance and immune dynamics in high-grade serous ovarian cancer
    Imbach, Kathleen J.
    Naganathan, Vikram
    Bernabeu, Arola Fortian
    Grases, Daniela
    Bernat-Peguera, Adria
    Bystrup, Sara
    Sibai, Mustafa
    Almeida, Lorena Valdivieso
    Romeo, Margarita
    Pardo, Eduard Porta
    Ginesta, Jordi Barretina
    CANCER RESEARCH, 2024, 84 (05)
  • [22] High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis
    Guo, Wenwen
    He, Xue
    Ni, Jing
    Ma, Liya
    Cheng, Xianzhong
    Wang, Congyang
    Chen, Xiaoxiang
    Wang, Yan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] A Tumor-Genetic Signature of Patients' Prognosis and Response to a Platinum-Based Treatment in High-Grade Ovarian Cancer
    Roncato, R.
    Toffoli, G.
    Montico, M.
    Gagno, S.
    Garziera, M.
    Poletto, E.
    De Mattia, E.
    Sorio, R.
    Canzonieri, V.
    Giorda, G.
    Cecchin, E.
    PUBLIC HEALTH GENOMICS, 2016, 19 : 7 - 7
  • [24] Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response
    Hua Yang
    Xiangyu Gu
    Rong Fan
    Qun Zhu
    Sen Zhong
    Xirun Wan
    Qian Chen
    Lan Zhu
    Fengzhi Feng
    Journal of Ovarian Research, 16
  • [25] Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response
    Yang, Hua
    Gu, Xiangyu
    Fan, Rong
    Zhu, Qun
    Zhong, Sen
    Wan, Xirun
    Chen, Qian
    Zhu, Lan
    Feng, Fengzhi
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [26] Impact of humoral immune response against p53 on clinical outcome of High-Grade Serous Ovarian Cancer (HGSOC) patients
    Garziera, M.
    Cecchin, E.
    Montico, M.
    Roncato, R.
    Gagno, S.
    De Mattia, E.
    Sorio, R.
    Scalone, S.
    Poletto, E.
    Toffoli, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
    Shakfa, Noor
    Li, Deyang
    Conseil, Gwenaelle
    Lightbody, Elizabeth D.
    Wilson-Sanchez, Juliette
    Hamade, Ali
    Chenard, Stephen
    Jawa, Natasha A.
    Laight, Brian J.
    Afriyie-Asante, Afrakoma
    Tyryshkin, Kathrin
    Koebel, Martin
    Koti, Madhuri
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (04)
  • [28] Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
    Wong-Brown, Michelle W.
    van der Westhuizen, Andre
    Bowden, Nikola A.
    BMC CANCER, 2022, 22 (01)
  • [29] Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer
    Kim, Hyun-Soo
    Kim, Ji-Ye
    Lee, Yong Jae
    Kim, So Hee
    Lee, Jung-Yun
    Nam, Eun Ji
    Kim, Sunghoon
    Kim, Sang Wun
    Kim, Young Tae
    GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 414 - 421
  • [30] Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
    Michelle W. Wong-Brown
    Andre van der Westhuizen
    Nikola A. Bowden
    BMC Cancer, 22
12345